Therapeutic observation and pharmacoeconomic analysis of two first-line chemo-therapy regimens in advanced NSCLC

VernacularTitle:晚期非小细胞肺癌两种一线化疗方案的疗效观察和药物经济学分析
Author: Wenyu ZHU ¹ ; Qi JIANG ; Liang ZHANG ; Juan WU ; Jie WANG ; Hongzi DING
Author Information

1. 江苏省南京市胸科医院药学部
Keywords: advanced non-small cell lung cancer(NSCLC); chemotherapeutic regimen; cost-effectiveness analysis
From: Journal of Pharmaceutical Practice 2018;36(2):176-179
CountryChina
Language:Chinese
Abstract: Objective To evaluate the cost-effectiveness of two chemotherapy regimens in NSCLC for the purpose of lower cost,higher quality medical care.Methods 56 patients with advanced NSCLC were divided into two groups from our hospital,group PP(pemtrexal+cisplatin,n=30)and group GP(gemcitabine+cisplatin,n=26),and analyzed by pharmaco-economic cost-effectiveness method,and retrospective analysis was also applied.Results Effective rates of two regimens were 46.67%,42.31%,no significant difference.But there was significant difference in the incidence rate of ADR between the two groups.The cost of chemotherapy regiments were 31 985.48 and 27 683.15 yuan.The average length of stay was 10.94 and 13·91 days.Compared to group GP,for each unit of efficacy,the cost in group PP were increased 986.77 yuan.Conclusion From the analysis of cost-effectiveness,group PP had higher chemotherapy costs,but better safety than group GP.